Phaseline

Companies › Anwita Biosciences

Anwita Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AWT020–Phase 1Advanced Cancer; Advanced Cancers (Solid Tumors)Jan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06092580AWT020Phase 1Advanced CancerOncologyJun 2026
NCT07822919AWT020Phase 1Advanced Cancers (Solid Tumors)OncologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.